Table 2.

Treatment effect of different trial characteristics included in this meta-analysis

	LV ejection fraction (%)			LV end-diastolic volume index (mL/m2)			LV end-systolic volume index (mL/m2)
	n	Treatment effect (95% CI)	P-value*	n	Treatment effect (95% CI)	P-value*	n	Treatment effect (95% CI)	P-value*
Time from PCI to cell infusion
<7 days	836	1.46 (0.41 to 2.51)	0.08	802	−3.53 (−5.89 to −1.18)	0.62	802	−2.88 (−4.70 to −1.06)	0.41
≥7 days	769	2.69 (1.80 to 3.58)		640	−4.36 (−6.66 to −2.05)		640	−3.94 (−5.69 to −2.19)
Total number of injected BMC
<1 × 108	314	2.80 (0.79 to 4.80)	0.05	314	−4.72 (−8.15 to −1.29)	0.34	314	−6.36 (−9.46 to −3.27)	0.01
≥1 × 108	1005	0.58 (−0.44 to 1.59)		1005	−2.78 (−4.85 to −0.70)		927	−1.97 (−3.58 to −0.36)
Imaging modality for LV function
MRI	981	0.16 (−0.88 to 1.20)	<0.001	976	−1.50 (−3.82 to 0.82)	0.02	976	0.16 (−1.54 to 1.85)	<0.001
Other	513	4.67 (3.69 to 5.66)		451	−5.63 (−8.11 to −3.15)		373	−5.85 (−7.69 to −4.01)
Study design
Blinded	558	1.36 (−0.04 to 2.76)	0.05	558	−1.93 (−4.96 to 1.09)	0.24	480	−2.41 (−4.60 to −0.21)	0.84
Open label	936	2.97 (2.14 to 3.80)		869	−4.11 (−6.16 to −2.06)		869	−2.69 (−4.20 to −1.17)

BMC, bone marrow cells; CI, confidence interval; LV, left ventricular; MRI, magnetic resonance imaging; n, number of patients; PCI, percutaneous coronary intervention.

*P-value for subgroup differences.